LPCN
Lipocine Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.18
−2.03%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.32
- Revenue estimate
- $219.0K
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.32
- EPS estimate
- -$0.40
- Revenue actual
- $190.1K
- Revenue estimate
- $213.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +13.3%
- Revenue beats (12Q)
- 3
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.40 | -$0.32 | Beat 20.00% | $190.1K |
| May 7, 2026 | -$0.51 | -$0.54 | Miss -5.88% | $1.2M |
| Mar 9, 2026 | -$0.61 | -$0.34 | Beat 44.26% | $1.1M |
| Nov 6, 2025 | -$0.56 | -$0.59 | Miss -5.36% | $114.6K |
| May 8, 2025 | -$0.35 | -$0.35 | In line | $93.9K |
| Mar 13, 2025 | -$0.40 | $0.33 | Beat 182.50% | $3.5M |
| Nov 7, 2024 | -$0.48 | -$0.44 | Beat 8.33% | — |
| Aug 8, 2024 | -$0.78 | -$0.56 | Beat 28.21% | $89.6K |
| May 9, 2024 | -$0.68 | $0.66 | Beat 197.06% | $7.6M |
| Mar 7, 2024 | -$0.53 | -$0.42 | Beat 20.75% | $216.2K |
| Nov 8, 2023 | -$0.57 | -$1.27 | Miss -122.81% | -$3.1M |
| Aug 10, 2023 | -$0.64 | -$0.68 | Miss -6.25% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026